Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.

导出 OA

翻译打印收藏纠错

作者： Pablo E,Serrano ^[1] ; Joseph M,Herman ^[2] ; Kent A,Griffith ^[3] ; Mark M,Zalupski ^[3] ; Edward J,Kim ^[4] ; Tanios S,Bekaii-Saab ^[5] ; Edgar,Ben-Josef ^[4] ; Laura A,Dawson ^[6] ; Jolie,Ringash ^[7] ; Alice C,Wei ^[8]

作者单位： Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada. ^[1] Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. ^[2] Center for Cancer Biostatistics, Biostatistics Unit, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan. ^[3] Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan. ^[4] Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio. ^[5] Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. ^[6] Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. ^[7] Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. Electronic address: alice.wei@uhn.ca. ^[8]